Sherwin Silo

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Glucagon nasal powder (GNP), a novel intranasal formulation of glucagon being developed to treat insulin-induced severe hypoglycemia, contains synthetic glucagon (10 % w/w), beta-cyclodextrin, and dodecylphosphocholine. The safety of this formulation was evaluated in four studies in animal models. The first study evaluated 28-day sub-chronic toxicology in(More)
  • 1